

# UTILITY PATENT APPLICATION TRANSMITTAL

## (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
0570.00077

Total Pages in this Submission  
74

### TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application  
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

**GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT**

and invented by:

Richard B. Silverman  
Ryszard Andruszkiewicz  
Po-Wai Yuen

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 08/899,918

Which is a:

☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 08/420,905

Which is a:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 08/064,285 (ABD)

Which is a: CIP of prior application No.: 07/886,080 (ABD)

Which is a: CIP of prior application No.: 07/618,692 (ABD)

Enclosed are:

### Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 57 pages and including the following:
  - a. ☒ Descriptive Title of the Invention
  - b. ☐ Cross References to Related Applications (if applicable)
  - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
  - d. ☐ Reference to Microfiche Appendix (if applicable)
  - e. ☒ Background of the Invention
  - f. ☒ Brief Summary of the Invention
  - g. ☐ Brief Description of the Drawings (if drawings filed)
  - h. ☒ Detailed Description
  - i. ☒ Claim(s) as Classified Below
  - j. ☒ Abstract of the Disclosure

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" mailing label number EL 187 077079 US

Date of Deposit: 2-4-99  
I hereby certify that the paper on file is being deposited with the United States Postal Service "Express Mail Post Office To Addressee" service under 37 CFR 1.10 on the date indicated above and is being sent to the Assistant Commissioner for Patents, Washington, D.C. 20231.

(Signature of person mailing paper or fee)

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
0570.00077

Total Pages in this Submission  
74

## Application Elements (Continued)

3. ☐ Drawing(s) (when necessary as prescribed by 35 USC 113)
- a. ☐ Formal Number of Sheets \_\_\_\_\_
- b. ☐ Informal Number of Sheets \_\_\_\_\_
4. ☒ Oath or Declaration
- a. ☐ Newly executed (original or copy) ☐ Unexecuted
- b. ☒ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
- d. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application,  
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☒ Incorporation By Reference (usable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied  
under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby  
incorporated by reference therein.
6. ☐ Computer Program in Microfiche (Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
- a. ☐ Paper Copy
- b. ☐ Computer Readable Copy (identical to computer copy)
- c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

## Accompanying Application Parts

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
- ☐ First Class ☒ Express Mail (Specify Label No.): EL 187 077079 US

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
0570.00077

Total Pages in this Submission  
74

**Accompanying Application Parts (Continued)**

15. ☐ Certified Copy of Priority Document(s) *(if foreign priority is claimed)*

16. ☒ Additional Enclosures *(please identify below):*


Copy of preliminary amendment adding claims 38-51 from parent application

**Fee Calculation and Transmittal**

**CLAIMS AS FILED**

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	8	- 20 =	0	x \$18.00	\$0.00
Indep. Claims	3	- 3 =	0	x \$78.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$760.00
OTHER FEE (specify purpose)					\$0.00
TOTAL FILING FEE					\$760.00

- ☒ A check in the amount of \$760.00 to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 11-1449 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

  
Signature

Kenneth I. Kohn, Reg. No. 30,955  
30500 Northwestern Highway, Suite 410  
Farmington Hills, Michigan 48334  
(248) 539-5050

Dated: 2-4-99

CC:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Silverman et al.

EI032481051US

Divisional of U.S.S.N. 08/420,905

Filed April 11, 1995

Group: 1204

Filed: Herewith

Examiner: Shippen, M.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

For: GABA AND L-GLUTAMIC ACID ANALOGS FOR "EXPRESS MAIL" Mailing Label Number EI032481051US  
ANTISEIZURE TREATMENT

Date of Deposit 7-24-97

PRELIMINARY AMENDMENT

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office To Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Assistant Commissioner for Patents  
Washington, D.C. 20231

Suzanne M. Trudel

*Suzanne M. Trudel*  
(Signature of person mailing paper or fee)

Dear Sir:

Please amend the above-identified application prior to consideration of the application on the merits.

IN THE SPECIFICATION:

Please insert the following paragraph before the Cross-Reference to Related Applications sections:


--GRANT INFORMATION

This invention was made with Government support under Grant No. NS15703 awarded by the National Institutes of Health. The Government has certain rights in the invention--.

IN THE CLAIMS:

Please cancel claims 1-37 and add the following new claims:

38. A method of treating a patient having anxiety disorders which comprises administering to said patient an effective amount of a compound of the formula



wherein  $R_{11}$  is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl group having from 3 to 6 carbon atoms;  $R_{12}$  is hydrogen or methyl; and  $R_{13}$  is hydrogen, methyl, or carboxyl; individual enantiomers thereof; and pharmaceutically acceptable salts thereof.

39. The method of Claim 38 wherein  $R_{11}$  is a straight or branched alkyl group having from 1 to 6 carbon atoms.

40. The method of Claim 38 wherein the alkyl group has 4 carbon atoms.

41. The method of Claim 40 wherein the compound is 4-amino-3-(2-methylpropyl) butanoic acid.

42. The method of Claim 41 wherein the compound is R-(~~-~~)-4-amino-3-(2-methylpropyl) butanoic acid.


43. The method of Claim 41 wherein the compound is S-(+)-4-amino-3-(2-methylpropyl) butanoic acid.

44. A method of treating a patient having Huntington's Disease which includes administering to the patient an effective amount of a compound selected from the following formula




wherein R<sub>11</sub> is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R<sub>12</sub> is hydrogen or methyl; and R<sub>13</sub> is hydrogen, methyl, or carboxyl; individual enantiomers thereof; and pharmaceutically acceptable salts thereof.

45. A method of treating a patient having depression disorders which includes administering to the patient an effective amount of a compound selected from the following formula




wherein R<sub>11</sub> is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R<sub>12</sub> is hydrogen or methyl; and R<sub>13</sub> is hydrogen, methyl, or carboxyl; individual enantiomers thereof; and pharmaceutically acceptable salts thereof.

1. ~~46.~~ A method of treating a patient having psychotic disorders which includes administering to the patient an effective amount of a compound selected from the following formula



wherein R<sub>11</sub> is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R<sub>12</sub> is hydrogen or methyl; and R<sub>13</sub> is hydrogen, methyl, or carboxyl; individual enantiomers thereof; and pharmaceutically acceptable salts thereof.

47. A method of treating a patient having cerebral ischemia which includes administering to the patient an effective amount of a compound selected from the following formula




wherein  $R_{11}$  is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms;  $R_{12}$  is hydrogen or methyl; and  $R_{13}$  is hydrogen, methyl, or carboxyl; individual enantiomers thereof; and pharmaceutically acceptable salts thereof.

48. A method of treating a patient having Parkinson's Disease which includes administering to the patient an effective amount of a compound selected from the following formula



wherein  $R_{11}$  is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms;  $R_{12}$  is hydrogen or methyl; and  $R_{13}$  is hydrogen, methyl, or carboxyl; individual enantiomers thereof; and pharmaceutically acceptable salts thereof.

49. A method of treating a patient having a dyskinesic condition which includes administering to the patient an effective amount of a compound selected from the following formula






wherein  $R_{11}$  is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms;  $R_{12}$  is hydrogen or methyl; and  $R_{13}$  is hydrogen, methyl, or carboxyl; individual enantiomers thereof; and pharmaceutically acceptable salts thereof.

50. A method of treating a patient having a spastic condition which includes administering to the patient an effective amount of a compound selected from the following formula



wherein  $R_{11}$  is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms;  $R_{12}$  is hydrogen or methyl; and  $R_{13}$  is hydrogen, methyl, or carboxyl; individual enantiomers thereof; and pharmaceutically acceptable salts thereof.

51. A method of increasing brain neuronal GABA in a patient which includes administering to the patient an effective amount of a compound selected from the following formula



wherein  $R_{11}$  is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms;  $R_{12}$  is hydrogen or methyl; and  $R_{13}$  is hydrogen, methyl, or carboxyl; individual enantiomers thereof; and pharmaceutically acceptable salts thereof.


### REMARKS

Claims 38-51 remain in the application. Claims 38, 44, 45, 46, 47, 48, 49, 50, and 51 are in independent form. Claims 1-37 have been canceled.

The application is in condition for allowance, which allowance is respectfully solicited.

Respectfully submitted,

KOHN & ASSOCIATES



Kenneth I Kohn  
Registration No. 30,955  
30500 Northwestern Hwy.  
Farmington Hills, MI 48334  
(248) 539-5050  
Date: 7-24-97

2. The method of claim [46] 1 wherein  $R_{11}$  is a straight or branched alkyl group having from 1 to 6 carbon atoms.

3. The method of claim [46] 1 wherein the alkyl group has 4 carbon atoms.

4. The method of claim [46] 1 wherein  $R_{11}$  is isobutyl.

5. The method of claim [46] 1 wherein  $R_{13}$  is hydrogen.

6. The method of claim [46] 1 wherein  $R_{12}$  is hydrogen.

7. A method of treating a patient having psychotic disorders which includes administering to a patient an effective amount of the compound R-(-)-4-amino-3-(2-methylpropyl) butanoic acid.

8. A method of treating a patient having psychotic disorders which includes administering to a patient an effective amount of the compound S-(+)-4-amino-3-(2-methylpropyl) butanoic acid.

GABA AND L-GLUTAMIC ACID ANALOGS FOR  
ANTISEIZURE TREATMENT

5 CROSS-REFERENCE TO RELATED APPLICATIONS

10 This application is a continuation-in-part of  
co-pending application U.S. Serial Number 886,080,  
filed May 20, 1992 which is a continuation-in-part of  
co-pending application U.S. Serial Number 618,692,  
filed November 27, 1990.

15 TECHNICAL FIELD

20 The present invention relates to novel compounds  
that are analogs of glutamic acid and gamma-  
aminobutyric acid (GABA). More specifically, the  
analogs are useful as antiseizure therapy for central  
nervous system disorders such as epilepsy, Huntington's  
chorea, cerebral ischemia, Parkinson's disease, tardive  
dyskinesia, and spasticity. It is also possible that  
the present invention could be used as an  
antidepressant, anxiolytic, and antipsychotic activity.

25 BACKGROUND OF THE INVENTION

30 Gamma aminobutyric acid (GABA) and glutamic acid  
are two major neurotransmitters involved in the  
regulation of brain neuronal activity. GABA is the  
major inhibitory neurotransmitter and L-glutamic acid  
is an excitatory transmitter (Roberts E, et al, GABA in  
Nervous System Function, Raven Press: New York, 1976;  
35 McGeer EG, et al, Glutamine, Glutamate, and GABA in the  
Central Nervous System; Hertz L, Kvamme E, McGeer EG,

Schousbal A, eds., Liss: New York, 1983;3-17). An imbalance in the concentration of these neurotransmitters can lead to convulsive states. Accordingly, it is clinically relevant to be able to control convulsive states by controlling the metabolism of this neurotransmitter. When the concentration of GABA diminishes below a threshold level in the brain, convulsions result (Karlsson A, et al, Biochem. Pharmacol 1974;23:3053-3061). When the GABA levels rise in the brain during convulsions, seizures terminate (Hayashi TJ, Physiol. (London) 1959;145:570-578). The term seizure as used herein means excessive unsynchronized neuronal activity that disrupts normal neuronal function. In several seizure disorders there is concomitant with reduced brain GABA levels a diminished level of L-glutamic acid decarboxylase (GAD) activity also observed (McGeer PO, et al, In: GABA in Nervous System Function; Roberts E, Chase TN, Tower DB, eds., Raven Press: New York 1976:487-495; Butterworth J, et al, Neurochem. 1983;41:440-447; Spokes EG, Adv. Exp. Med. Biol. 1978;123:461-473; Wu JY, et al, Neurochem. Res. 1979;4:575-586; and Iversen LL, et al, Psychiat. Res. 1974;11:255-256). Often, the concentrations of GAD and GABA vary in parallel because decreased GAD concentration results in lower GABA production.

Because of the importance of GABA as an inhibitory neurotransmitter, and its effect on convulsive states and other motor dysfunctions, a variety of approaches have been taken to increase the brain GABA concentration. For example, the most obvious approach was to administer GABA. When GABA is injected into the brain of a convulsing animal, the convulsions cease (Purpura DP, et al, Neurochem. 1959;3:238-268). However, if GABA is administered systematically, there is no anticonvulsant effect because GABA, under normal

circumstances, cannot cross the blood brain barrier (Meldrum BS, et al, Epilepsy; Harris P, Mawdsley C, eds., Churchill Livingstone: Edinburg 1974:55. In view of this limitation, there are three alternative approaches that can be taken to raise GABA levels.

The most frequent approach is to design a compound that crosses the blood brain barrier and then inactivates GABA aminotransferase. The effect is to block the degradation of GABA and thereby increase its concentration. Numerous mechanism-based inactivators of GABA aminotransferase are known (Silverman RB, Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology, Vol. I and II, CRC: Boca Raton 1988).

Another approach is to increase GABA concentrations in the brain by making GABA lipophilic by conversion to hydrophobic GABA amides (Kaplan JP, et al, G.J. Med. Chem. 1980;23:702-704; Carvajal G, et al, Biochem. Pharmacol. 1964;13:1059-1069; Imines: Kaplan JP, Ibid.; or GABA esters: Shashoua VE, et al, J. Med. Chem. 1984;27:659-664; and PCT Patent Application WO85/00520, published 2/14/85) so that GABA can cross the blood brain barrier. Once inside the brain, these compounds require amidase and esterases to hydrolyze off the carrier group and release GABA.

Yet another approach is to increase <sup>[25]</sup>brain GABA levels by designing an activator of GAD. A few compounds have been described as activators of GAD. The anticonvulsant agent, maleicimid, was reported to increase the activity of GAD by 11% and as a result increase GABA concentration in the substantia nigra by up to 38% (Janssens de Varebeke P, et al, Biochem. Pharmacol. 1983;32:2751-2755. The anticonvulsant drug sodium valproate (Loscher W, Biochem. Pharmacol. 1982;31:837-842; Phillips NI, et al, Biochem. Pharmacol. 1982;31:2257-2261) was also reported to activate GAD and increase GABA levels.


The compounds of the present invention have been found to activate GAD in vitro and have a dose dependent protective effect on-seizure in vivo.

Also, the compounds of the present invention have been found to bind a novel binding site which was identified to bind tritiated gabapentin. Gabapentin has been found to be an effective treatment for the prevention of partial seizures in patients refractory to other anticonvulsant agents. Chadwick D, Gabapentin, pp. 211-222, In: Recent Advances in Epilepsy, Vol. 5, Pedley TA, Meldrum BS, (eds.) Churchill Livingstone, New York (1991). The novel binding site labeled by tritiated gabapentin was described in membrane fractions from rat brain tissue and in autoradiographic studies in rat brain sections, Hill D, Ibid. This binding site has been used to evaluate the compounds of the present invention.

The novel compounds of the present invention are set forth below as Formula I. It should be noted that the compound of Formula I wherein R<sub>1</sub> is methyl and each of R<sub>2</sub> and R<sub>3</sub> is hydrogen is taught in Japan Patent Number 49-40460.

#### SUMMARY OF THE INVENTION

In accordance with the present invention, there is provided compounds of the Formula I




wherein R<sub>1</sub> is a straight or branched alkyl of from 1 to 6 carbons, phenyl or cycloalkyl having from 3 to 6 carbon atoms; R<sub>2</sub> is hydrogen or methyl; and R<sub>3</sub> is

hydrogen, methyl, or carboxyl; with the proviso that when each of the  $R_2$  and  $R_3$  is hydrogen,  $R_1$  is other than methyl. Pharmaceutically acceptable salts of the compounds of Formula I are also included within the scope of the present invention. Also included within the scope of the present invention are the individual enantiomeric isomers of the compounds of the Formula I.

The present invention also provides pharmaceutical compositions of the compounds of Formula I.

Also provided as a part of the present invention is a novel method of treating seizure disorders in a patient by administering to said patient an anticonvulsant effective amount of a compound of the following Formula II



wherein  $R_{11}$  is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms;  $R_{12}$  is hydrogen or methyl; and  $R_{13}$  is hydrogen, methyl, or carboxyl; or an individual enantiomeric isomer thereof; or a pharmaceutically acceptable salt thereof.

Also, the present invention provides a method for increasing brain neuronal GABA and provides pharmaceutical compositions of the compounds of Formula II.

The present invention provides novel processes for the synthesis of chiral Formula I compounds.



DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there is provided a series of 3-alkyl-4-aminobutyric acid or 3-alkyl glutamic acid analogs which are useful as anticonvulsants. Illustrative of the alkyl moieties as represented by  $R_1$  and  $R_{11}$  in Formulas I and II are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, isopentyl, and neopentyl as well as other alkyl groups. The cycloalkyl groups represented by  $R_1$  and  $R_{11}$  in Formulas I and II are exemplified by cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The analogs are further shown herein to prevent seizure while not causing the side effect of ataxia, such a side effect being found in several anti-seizure pharmaceuticals.

The more preferred compounds of the present invention are of Formula I above wherein  $R_3$  is hydrogen,  $R_2$  is hydrogen, and  $R_1$  isobutyl.

That is, the preferred compound is 4-amino-3-(2-methylpropyl)butanoic acid. It has been found that this compound is unexpectedly more potent than the other analogs synthesized in accordance herewith and tested in vivo. What is further surprising, as the following data shows, is that this preferred compound is the least effective one of the analogs tested in activating GAD in vitro. Accordingly, it was very unexpected that this preferred compound had such a high potency when tested in vivo.

The most preferred compounds of the present invention are the (S)-(+)- and the (R)(-)-4-amino-3-(2-methylpropyl)butanoic acid with the (S)-(+)-enantiomer being most preferred. The (S)-(+)-enantiomer was found to be the most potent compound within the scope of the present invention for displacement of tritiated gabapentin, and both the

(S) - (+) - and the (R) - (-) - enantiomers showed pronounced stereoselectivity for both displacement of tritiated gabapentin and for anticonvulsant activity in vivo.

The compounds made in accordance with the present invention may form pharmaceutically acceptable salts with both organic and inorganic acids or bases. For example, the acid addition salts of the basic compounds are prepared either by dissolving the free base in aqueous or aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution. Examples of pharmaceutically acceptable salts are hydrochlorides, hydrobromide, hydrosulfates, etc, as well as sodium, potassium, and magnesium, etc, salts.

The method for the formation of the 3-alkyl-4-aminobutanoic acids starting from 2-alkanoic esters is prepared from commercially available aldehydes and monomethyl malonate by the Knoevenagel reaction, (Kim YC, et al, J. Med. Chem. 1965:8509) with the exception of ethyl 4,4-dimethyl-2-pentenoate.

More specifically, the following is a procedure which can be generally applied to the preparation of all the 3-alkylglutamic acids. Ten grams of a 3-alkyl-5,5-dicarbethoxy-2-pyrrolidinone was refluxed in 150 mL of 49% fuming HBr for 4 hours. After this time, the contents were placed in an evaporator and the volatile constituents were removed in vacuo with the aid of a hot-water bath. The gummy residue was dissolved in 25 mL of distilled water and the water was removed with the aid of the evaporator. This process was repeated once more. The residue was dissolved in 20 mL of water, and the pH of the solution was adjusted to 3.2 with concentrated  $\text{NH}_3$  solution. At this point the chain length of the individual 3-alkylglutamic acids altered the solubility so that those whose side chains were larger precipitated with the ease from solution.

Precipitation of the alkylglutamic acids with smaller substituents (methyl, ethyl, and propyl) could be encouraged by cooling on an ice bath or by diluting the aqueous solution with 100 mL of absolute ethanol.

5 Precipitation from the water-alcohol mixture is complete in 48 hours. Care must be taken to add the ethanol slowly to prevent the precipitation of an amorphous solid which is not characteristic of the desired 3-alkylglutamic acids. Samples of the amino  
10 acids were purified for analysis by recrystallizing from a water-ethanol mixture. All melted with decomposition. Melting points of the decomposed 3-alkylglutamic acids corresponded with those of their pyroglutamic acids.

15 Ethyl 4,4-dimethyl-2-pentenoate was prepared from 2,2-dimethylpropanol and ethyl lithioacetate, followed by dehydration of the  $\beta$ -hydroxy ester with phosphoryl chloride and pyridine.

20 The Michael addition of nitromethane to  $\alpha$ ,  $\beta$ -unsaturated compounds mediated by 1,1,3,3-tetramethylguanidine or 1,8-diazabicyclo-[5.4.0]undec-7-ene (DBU) afforded 4-nitroesters in good yields. More specifically, a mixture of nitromethane (5 mol),  $\alpha$ ,  $\beta$ -unsaturated ester (1 mol), and  
25 tetramethyl-guanidine (0.2 mol) was stirred at room temperature for 2 to 4 days. (In case of methyl acrylate, the ester has to be added at a temperature below 300.) The progress of the reaction was followed by IR (disappearance of the C=C band) and G.L.C.  
30 analysis. The reaction mixture was washed with dilute hydrochloric acid and extracted with ether. The organic extract was dried, the solvent removed at reduced pressure, and the 20 residue distilled at a pressure of 2 torr. Although the aliphatic nitro  
35 compounds are usually reduced by either high pressure catalytic hydrogenation by metal-catalyzed transfer

hydrogenation, or by newly introduced hydrogenolysis methods with ammonium formate or sodium borohydride and palladium as catalysts, applicants have found that 4-nitrocarboxylic esters can be reduced almost quantitatively to the corresponding 4-aminocarboxylic esters by hydrogenation using 10% palladium on carbon as catalysts in acetic acid at room temperature and atmospheric pressure. The amino esters produced were subjected to acid hydrolysis to afford the subject inventive compounds in good yields. This procedure provides access to a variety of 3-alkyl-4-aminobutanoic acids as listed in Tables 1 and 2 as examples and thus is advantageous in comparison to methods previously used.

Examples of more specific methods of making compounds in accordance with the present invention are as follows, optionally utilizing the methods described in detail above. When the starting material is not commercially available, the synthetic sequence may be initiated with the corresponding alcohol, which is oxidized to the aldehyde by the method of Corey EJ, et al, Tetrahedron Lett. 1975:2647-2650.

The chiral compounds of Formulas I and II are prepared as set forth in the schematic in Chart I hereof. Although the schematic in Chart I depicts the chiral synthesis of specific compound (S)-(+)-4-amino-3-(2-methylpropyl)butanoic acid, one skilled in the art can readily see that the method of synthesis can be applied to any diastereomeric compound of Formulas I and II.

In Chart I Ph is phenyl, Bn is benzyl, THF is tetrahydrofuran, LDA is lithium diisopropylamide,  $\text{BH}_3 \cdot \text{SMe}_2$  is borane dimethyl sulfide complex, TsCl is tosyl chloride, and DMSO is dimethylsulfoxide.

The detailed synthetic procedure is set forth hereinbelow in Example 1. The key introductory

literature for this methodology was discussed in Evans' paper, J. Am. Chem. Soc. 1982;104:1737-9. The metal enolate can be formed with a lithium or sodium amide base, and subsequently alkylated to give an a substituted carboxylic acid derivative. This methodology was valuable for the enantioselective synthesis of these  $\alpha$ -substituted carboxylic acid derivatives. In this seminal paper, Evans described the preparation of propionic acid derivatives with a series of simple alkylating agents. By varying the stereochemistry of the chiral synthon (the oxazolidinone), he was able to get high stereoselectivity.

Evans has used this chiral auxiliary in other synthetic studies, but none has been related to 4-amino-3-(2-methylpropyl)butanoic acid which contains a  $\beta$ -substituted- $\gamma$ -amino acid. The methodology as presented by Evans teaches toward  $\alpha$ -substitution, and away from  $\beta$ -substitution, and has not been used in the preparation of this type of unusual amino acid. N-acyloxazolidinones have been used to form chlorotitanium enolates that have been reacted with Michael adducts such as acrylonitrile, J. Org. Chem. 1991;56:5750-2. They have been used in the synthesis of the rutamycin family of antibiotics, J. Org. Chem. 1990;55:6260-8 and in stereoselective aldol condensations, Org. Synth. 1990;68:83-91. Chiral  $\alpha$ -amino acids were prepared via the oxazolidinone approach. In this sequence, a dibutylboron enolate was brominated and displaced with azide, Tetrahedron Lett. 1987;28:1123-6. Other syntheses of  $\beta$ -hydroxy- $\alpha$ -amino acids were also reported via this chiral auxiliary through aldol condensation (Tetrahedron Lett. 1987;28:39-42; J. Am. Chem. Soc. 1987;109:7151-7).  $\alpha,\beta$ -Unsaturated N-acyloxazolidinones have also been used to induce chirality in the Diels-Alder reaction,

(J. Am. Chem. Soc. 1988;110:1238-56. In none of these examples, or others found in the literature, is this methodology used to prepare ( $\beta$ -substituted carboxylic acids or 3-substituted GABA analogs.

5 In another embodiment, the chiral compounds of Formulas I and II can be prepared in a manner which is similar to the synthesis depicted in Chart I. In this embodiment, however, step 8 in Chart I is replaced by an alternate two step procedure which is set forth  
10 hereinbelow in Example 2 (sodium hydroxide is preferred, however, other solvents known to those of skill in the art which can hydrolyze the azide (8) to intermediate azide (8a) can be employed).. Instead of reducing the azide (8) to the amino acid (9) in  
15 Chart I, the alternate procedure hydrolyzes the azide (8) to give an intermediate azide (8a) which is subsequently reduced (see Chart Ia).

There are <sup>two</sup>2 major advantages to hydrolyzing azide (8) to give the intermediate azide (8a) prior to  
20 reduction. The first advantage is that intermediate azide (8a) may be purified by extraction into aqueous base. After the aqueous extract is acidified, intermediate azide (8a) may be extracted into the organic phase and isolated. This allows for a  
25 purification of intermediate azide (8a) which does not involve chromatography. The purification of azide (8) requires chromatography which is very expensive and often impractical on a large scale.

The second advantage is that intermediate azide  
30 (8a) may be reduced to amino acid (9) without added acid. Reduction of azide (8) requires addition of acid, e.g., hydrochloric acid in order to obtain amino acid (9). Unfortunately, lactamization of amino acid (9) is promoted by the presence of acid. Intermediate  
35 azide (8a) may be reduced under near neutral conditions

5


10

15

25

30

35



Still another advantage, which was previously discussed with regard to the synthetic procedure depicted by Chart Ia, is that the t-butyl synthetic route minimizes the problem of lactam formation of the amino acid end product (109). Instead of reducing azide (108) to amino acid (109) which requires the addition of acid that causes lactamization of amino acid (109), azide (108) is first hydrolyzed to intermediate azide (108a). Intermediate azide (108a) may be reduced under neutral conditions to give amino acid (109), thus minimizing the problem of lactam formation.

It should also be mentioned that several novel intermediates are produced by the processes discussed herein. Some of these intermediates which are depicted in Charts I, Ia, and II include in the racemate or R or S enantiomer form:

- 4-methyl-5-phenyl-2-oxazolidinone,
- 4-methyl-(2-methylpropyl)-2-dioxo-5-phenyl-3-oxazolidine butanoic acid, phenylmethyl ester,
- 4-methyl-pentanoyl chloride,
- 4-methyl-3-(4-methyl-1-oxopentyl)-5-phenyl-2-oxazolidinone,
- 2-(2-methylpropyl)-butanedioic acid,
- 4-(phenylmethyl)ester,
- 3-(azidomethyl)-5-methyl-hexanoic acid, phenylmethyl ester,
- 3-(hydroxymethyl)-5-methyl-hexanoic acid, phenylmethyl ester,



5-methyl-3-[[[(4-methylphenyl)sulfonyl]oxy]-methyl]-hexanoic acid, phenylmethyl ester,

3-(azidomethyl)-5-methyl-hexanoic acid,

2-(2-methylpropyl)-1,4-butanedioic acid,

5 4-(1,1-dimethylethyl) ester,

3-(azidomethyl)-5-methyl-, 1,1-dimethylethyl ester,

3-(hydroxymethyl)-5-methyl-hexanoic acid, 1,1-dimethyl ester,

10 5-methyl-3-[[[(4-methyl(phenyl)sulfonyl]oxy)-methyl]-hexanoic acid, 1,1-dimethylethyl ester, or

4-methyl-(2-methylpropyl)-2-dioxo-5-phenyl-3-oxazolidinebutanoic acid, 1,1-dimethylethyl ester.

The compounds made by the aforementioned synthetic  
15 methods can be used as pharmaceutical compositions as an antidepressant, anxiolytic, antipsychotic, antiseizure, antidyskinetic, or antisymptomatic for Huntington's or Parkinson's diseases when an effective amount of a compound of the aforementioned formula  
20 together with a pharmaceutically acceptable carrier is used. That is, the present invention provides a pharmaceutical composition for the suppression of seizures resulting from epilepsy, the treatment of cerebral ischemia, Parkinson's disease, Huntington's  
25 disease and spasticity and also possibly for antidepressant, anxiolytic, and antipsychotic effects. These latter uses are expected due to functional similarities to other known compounds having these pharmacological activities. The pharmaceutical can be  
30 used in a method for treating such disorders in mammals, including human, suffering therefrom by administering to such mammals an effective amount of the compound as described in Formulas I and II above in unit dosage form.

35 The pharmaceutical compound made in accordance with the present invention can be prepared and

administered in a wide variety of dosage forms. For example, these pharmaceutical compositions can be made in inert, pharmaceutically acceptable carriers which are either solid or liquid. Solid form preparation include powders, tablets, dispersible granules, capsules, cachets, and suppositories. Other solid and liquid form preparations could be made in accordance with known methods of the art. The quantity of active compound in a unit dose of preparation may be varied or adjusted from 1 mg to about 300 mg/kg (milligram per kilogram) daily, based on an average 70 kg patient. A daily dose range of about 1 mg to about 50 mg/kg is preferred. The dosages, however, may be varied depending upon the requirement with a patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for particular situations is within the skill of the art.

Illustrative examples of compounds made in accordance with the present invention were tested to demonstrate the ability of the compounds to activate GAD in vitro and to prevent seizure in vivo without the side effect of ataxia.

#### In Vitro GAD Activation

Assays were carried out in 10 mL vials sealed with serum caps through which a center well (Kontes Catalog No. 882320-000) was inserted. The center well was charged with 200  $\mu$ L of freshly prepared 8% KOH solution. Various concentrations of L-glutamic acid (0.5, 0.25, 0.166, 0.125, 0.10 mM) containing [ $^{14}$ C]L-glutamate (10  $\mu$ Ci/mmol) in 50 mM potassium phosphate buffer, pH 7.2 were shaken at 37°C in separate vials with purified L-glutamic acid decarboxylase (18.75  $\mu$ g; spec. act 10.85  $\mu$ mol/min mg) in a total volume of 2.00 mL. After being shaken for

60 minutes, the enzyme reactions were quenched by the addition of 200  $\mu$ L of 6 M sulfuric acid to the contents of each of the vials. The vials were shaken for an additional 60 minutes at 37°C. The center wells were removed and placed in scintillation vials with 10 mL of scintillation fluid for radioactivity determination. The same assays were repeated except in the presence of various concentrations of the activators (2.5, 1.0, 0.5, 0.25, 0.1, 0.05 mM). The Vmax values were determined from plots of 1/cpm versus 1/[glutamate] at various concentrations of activators. The data were expressed as the ratio of the Vmax in the presence of the activators to the Vmax in the absence of the activators times 100%.

The results of the experiment are shown in Table 1. The tests show that there was significant activation by the various compounds tested to differing degrees. The known activator sodium valproate and gabapentin were tested.

In vivo tests were performed to demonstrate the seizure preventing capabilities of the novel compounds. Threshold maximum electroshock is an animal model test for generalized seizures that is similar to that of Piredda SG, et al, Pharmacol. and Exptl. Therap. 1985;232(3):741-45. The methods for this test are described as follows.

Male CF-1 mice (22-30 g) were allowed free access to food and water prior to testing. For screening, groups of five mice were given a compound intravenously at doses of 30, 100, and 300 mg/kg and tested at 0.5, 2.0, and 4.0 hours after dosing. Drugs were either dissolved in 0.9% saline or suspended in 0.2% methylcellulose. Animals were shocked with corneal electrodes (see below) and observed for tonic hindlimb extensor seizures. Absence of hindlimb extension was taken as an anticonvulsant effect.

The electroshock apparatus delivered a 60 Hz sine wave with a current amplitude of 14 mA (peak-to-peak) for 0.2 seconds. The current strength of 14 mA used in this procedure produced tonic extensor seizures in approximately 95% of untreated mice, but was only slightly above threshold for tonic extension.

Summaries of the numbers of animals protected from seizures when tested 120 minutes after administration of each compound set forth in the left-hand column are given in Table 2 for varying dose levels set forth in the second column of the table.

Due to the interesting phenomena related to the (R,S)-i-butyl GABA (the compound having significantly higher potency and effectiveness without causing ataxia), threshold maximal electroshock tests were conducted varying the time of testing from 1 hour to 8 hours, the dose being 10 mg/kg in mice, injected intravenously. Table 3 shows the results of these tests indicating a maximum protection after 2 hours of testing.

In view of the above results, a dose response curve was made for the <sup>two</sup> 2 hour testing time period in mice, the drug being given intravenously at 10 mg/kg. The results of this test is shown in Table 4 with a calculated ED<sub>50</sub> equaling 2.07 mg/kg.

A third pharmacological test was performed as described in Krall RL, et al, Epilepsia. 1978;19:409. In this procedure, drugs were tested for attenuation of threshold clonic seizures in mice caused by subcutaneous administration of pentylenetetrazol (85 mg/kg) which is a generally accepted model for absence type seizures. Results from the third test for the compound when administered either intravenously or orally is shown in Table 5. The test was conducted at three dose levels, showing effective protection at 30 mg/kg and 100 mg/kg with no ataxia.


The above is a significant finding because the compound having the least ability to activate GAD in vitro surprisingly had an approximately 10-fold increase in potency over the other compounds tested. Even more unexpected is the absence of ataxic side effect coupled to this increase in potency.

5

CONFIDENTIAL


TABLE 1

Activation of GAD by GABA analogs at various concentrations expressed in %




R <sub>1</sub> , R <sub>2</sub>	2.5 mM	1.0 mM	0.5 mM	0.25 mM	0.1 mM	0.05 mM
(R, S) -CH <sub>3</sub> , H	239	168	142	128	118	107
(R) -CH <sub>3</sub> H	327	202	185	135	128	109
(S) -CH <sub>3</sub> H	170	118	--	103	--	--
CH <sub>3</sub> , CH <sub>3</sub>	174	125	--	109	--	--
(R, S) -C <sub>2</sub> H <sub>5</sub> , H	172	128	--	108	--	--
(R, S) -n-C <sub>3</sub> H <sub>7</sub> , H	156	112	--	105	--	--
(R, S) -i-C <sub>3</sub> H <sub>7</sub> , H	140	108	--	104	--	--
(R, S) -n-C <sub>4</sub> H <sub>9</sub> , H	178	117	--	105	--	--
(R, S) -i-C <sub>4</sub> H <sub>9</sub> , H	143	113	--	109	--	--
(R, S) -s-C <sub>4</sub> H <sub>9</sub> , H	169	119	--	105	--	--
(R, S) -t-C <sub>4</sub> H <sub>9</sub> , H	295	174	147	121	117	108
(R, S) -neo-C <sub>5</sub> H <sub>11</sub> , H	279	181	--	130	--	--
(R, S) -i-C <sub>5</sub> H <sub>11</sub> , H	142	118	--	109	--	--
(R, S) -C <sub>6</sub> H <sub>11</sub> , H	125	100	--	100	--	--
(R, S) -C <sub>6</sub> H <sub>5</sub> , H	218	129	--	110	--	--

TABLE 1 (Cont.)



R	2.5 mM	1.0 mM	0.5 mM	0.25 mM	0.1 mM	0.05 mM
10 H(R,S)	140	111	--	104	--	--
H(R)	173	125	--	108	--	--
H(S)	100	100	--	100	--	--
CH <sub>3</sub>	143	121	--	109	--	--
C <sub>6</sub> H <sub>5</sub>	207	151	--	112	--	--
15 Sodium Valproate	207	138	124	119	115	105
GABAPENTIN	178	145	--	105	--	--

20 Activation of GAD by glutamate analogs expressed in %



R	2.5 mM	1.0 mM	0.25 mM
CH <sub>3</sub>	212	144	113
30 C <sub>2</sub> H <sub>5</sub>	170	128	113
n-C <sub>3</sub> H <sub>7</sub>	153	125	108
i-C <sub>3</sub> H <sub>7</sub>	144	114	105
n-C <sub>4</sub> H <sub>9</sub>	133	117	105
i-C <sub>4</sub> H <sub>9</sub>	129	112	106
35 C <sub>6</sub> H <sub>5</sub>	172	135	112
Sodium Valproate	207	138	119

TABLE 2

Prevention of tonic extensor seizures in mice  
following intravenous administration of  
3-substituted GABA derivatives

R	Dose (mg/kg)	Time After Dose (min)	Effect # Protected/ # Tested	Ataxia # Ataxia/ # Tested
(R, S) -CH <sub>3</sub>	10	120	0/5	0/5
	30	120	4/5	0/5
	100	120	3/5	0/5
CH <sub>3</sub>	1	120	1/10	0/10
	3	120	2/10	0/10
	10	120	4/10	0/10
	30	120	3/10	0/10
	100	120	3/10 (5/10)	1/10
CH <sub>3</sub>	10	120	1/10	1/10
	30	120	2/10	0/10
	100	120	5/10	0/10
t-C <sub>4</sub> H <sub>9</sub>	10	120	2/10	0/10
	30	120	2/10	0/10
	100	120	5/10	0/10
C <sub>2</sub> H <sub>5</sub>	3	120	1/5	0/5
	10	120	1/5	0/5
	30	120	2/5	0/5
	100	120	5/5	0/5
(CH <sub>3</sub> ) <sub>2</sub>	30	120	4/5	0/5
	100	120	4/5	0/5
n-C <sub>4</sub> H <sub>9</sub>	10	120	1/10	0/10
	30	120	3/10	0/10
	100	120	4/10	0/10



TABLE 2 (Cont.)

R	Dose (mg/kg)	Time After Dose (min)	Effect # Protected/ # Tested	Ataxia # Ataxia/ # Tested
S-C <sub>4</sub> H <sub>9</sub>	3	120	2/10	0/10
	10	120	3/10	0/10
	30	120	2/10	0/10
i-C <sub>4</sub> H <sub>9</sub>	0.3	120	1/10	0/10
	0.8	120	3/10	0/10
	2.0	120	5/10	0/10
	5.5	120	7/10	0/10
	14.4	120	9/10	0/10
n-C <sub>3</sub> H <sub>7</sub>	3	120	2/10	0/10
	10	120	2/10	3/10
	100	120	3/10	0/10
i-C <sub>3</sub> H <sub>7</sub>	10	120	5/10	1/10
	30	120	5/10	0/10
	100	120	6/10	0/10
C <sub>6</sub> H <sub>5</sub>	100	120	0/10	0/10
neo-C <sub>5</sub> H <sub>11</sub>	10	120	2/10	0/10
	30	120	4/10	0/10
	100	120	4/10	0/10

- High-intensity corneal electroshock consisted of 50 mA, base-to-peak sinusoidal current for 0.2 seconds. All other data was from low-intensity electroshock, 17 mA base-to-peak sinusoidal current for 0.2 seconds.

TABLE 3

Threshold maximal electroshock with  
isobutyl GABA

Time of Testing	# Protected
1 hr.	2/10
2 hr.	8/10
4 hr.	4/10
8 hr.	2/10

TABLE 4

Threshold maximal electroshock with  
isobutyl GABA

Dose m/k	# Protected
0.3	1/10
0.8	3/10
2.0	5/10
5.5	7/10
14.4	9/10

TABLE 5

Maximal electroshock data

R	Dose (mg/kg)	Time After Dose (min)	Effect # Protected/ # Tested	Ataxia # Ataxia/ # Tested
i-C <sub>4</sub> H <sub>9</sub>	10	120	1/5	0/5
i-C <sub>4</sub> H <sub>9</sub>	30	120	4/5	0/5
i-C <sub>4</sub> H <sub>9</sub>	100	120	4/5	0/5

As noted hereinabove, the S-(+) enantiomer of 4-amino-3-(2-methylpropyl)butanoic acid (3-isobutyl GABA or IBG) which is structurally related to the known anticonvulsant, gabapentin, potentially displaces tritiated gabapentin from a novel high-affinity site in rat brain membrane fractions. Also the S-(+) enantiomer of 3-isobutyl GABA is responsible for virtually all blockade of maximal electroshock seizures in mice and rats. The R(-) enantiomer of 3-isobutyl GABA is much less effective in the blockade of maximal electroshock seizures and in displacement of tritiated gabapentin from the novel high-affinity binding site. Table 6 below sets forth data comparing gabapentin, racemic 3-isobutyl GABA ((±)-IBG), S-(+)-3-isobutyl GABA ((S)-IBG) and R-(-)-3-isobutyl GABA ((R)-IBG) in these assays.

TABLE 6

Test System	3-Isobutyl GABA (ED <sub>50</sub> )			
	Gabapentin	(±) -IBG	(S) -IBG	(R) -IBG
Gabapentin Receptor Binding (IC <sub>50</sub> )	0.14 μM	0.10 μM	0.044 μM	0.86 μM
IV Mouse Low-Intensity Electroshock	4.3 mg/Kg	4.8 mg/Kg	4.0 mg/Kg	>100 mg/Kg
IV Mouse Maximal Electroshock	75 mg/Kg	10 mg/Kg	18 mg/Kg	>100 mg/Kg
PO Mouse Maximal Electroshock	200 mg/Kg	47 mg/Kg	12 mg/Kg	
IV Mouse Ataxia (IP)	>100 mg/Kg	>100 mg/Kg	>300 mg/Kg	>100 mg/Kg
Time course of anticonvulsant activity (all compounds) peaks 2.0 hours after dose and mostly gone 8 hours after dose.				

The data set forth in Table 6 was obtained as follows. For anticonvulsant testing, male CF-1 strain mice (20-25 g) and male Sprague-Dawley rats (75-115 g) were obtained from Charles River Laboratories and were maintained with free access to food and water before testing. Maximal electroshock was delivered with corneal electrodes by conventional methods (Krall, supra, 1975) except that low-intensity electroshock with mice consisted of 17 mA of current rather than the conventional 50 mA (zero to peak). Briefly, mice were given test substance and were tested for prevention of seizures by application of electrical current to the corneas by 2 metal electrodes covered with gauze and saturated with 0.9% sodium chloride. Electroshock stimulation was delivered by a constant-current device that produced 60 Hz sinusoidal electrical current for 0.2 seconds. For rats, maximal electroshock stimulation consisted of 120 mA of current. Ataxia in mice was assessed by the inverted screen procedure in which mice were individually placed on a 4.0-inch square of wire mesh that was subsequently inverted (Coughenour, supra, 1978). Any mouse that fell from the wire mesh during a 60 second test period was rated as ataxic. ED<sub>50</sub> values were determined by probit analysis of results with at least 5 dose groups of 10 mice or 8 rats each.

All drugs were freely soluble in aqueous media. For in vivo studies, drug solutions were made in 0.9% sodium chloride and given in a volume of 1 mL/100 g body weight. Intravenous administration was given by bolus injection into the retro-orbital sinus in mice. Oral administrations were by intragastric gavage.

For binding studies, partially purified synaptic plasma membranes were prepared from rat neocortex using sucrose density gradients. The cerebral cortex of 10 rats was dissected from the rest of the brain and

homogenized in 10 volumes (weight/volume) of ice-cold  
0.32 M sucrose in 5 mM tris-acetate (pH 7.4) using a  
glass homogenizer fitted with a teflon pestle  
(10-15 strokes at 200 rpm). The homogenate was  
centrifuged at 100 g for 10 minutes and the supernatant  
collected and kept on ice. The pellet (P1) was  
rehomogenized in 20 mL of tris-sucrose and the  
homogenate recentrifuged. The combined supernatants  
were centrifuged at 21,500 g for 20 minutes. The  
pellet (P2) was resuspended in 1.2 M tris-sucrose and  
15 mL of this mixture was added to ultracentrifuge  
tubes. On to this, 10 mL of 0.9 M sucrose was layered  
followed by a final layer of 5 mM tris-acetate, pH 8.0.  
Tubes were centrifuged at 100,000 g for 90 minutes.  
The synaptic plasma membranes located at the 0.9/1.2 M  
sucrose interface were collected, resuspended in 50 mL  
of 5 mM tris-acetate, pH 7.4, and centrifuged at  
48,000 g. The final pellet was resuspended in 50 mL of  
tris-acetate, pH 7.4, aliquoted, and then frozen until  
use.

The assay tissue (0.1 to 0.3 mg protein) was  
incubated with 20 mM [<sup>3</sup>H]-gabapentin in 10 mM HEPES  
buffer (pH 7.4 at 20°C, sodium free) in the presence of  
varying concentrations of test compound for 30 minutes  
at room temperature, before filtering onto GFB filters  
under vacuum. Filters were washed 3 times with 5 mL of  
ice cold 100 mM NaCl solution and dpm bound to filters  
was determined using liquid scintillation counting.  
Nonspecific binding was defined by that observed in the  
presence of 100 mM gabapentin.

In view of the above demonstrated activity of the  
compounds characterizing the present invention and in  
particular the 4-amino-3-(2-methylpropyl)butanoic acid  
(isobutyl GABA) the compounds made in accordance with  
the present invention are of value as pharmacological

agents, particularly for the treatment of seizures in mammals, including humans.

EXAMPLE 1

5     (S) - (+) - 4-amino-3-(2-methylpropyl)butanoic acid

      The following "steps", refer to Chart I.

Step 1

10       To a solution of 4-methylvaleric acid (50.0 g, 0.43 mol) in 100 mL of anhydrous chloroform was added thionyl chloride (60 mL, 0.82 mol). The reaction mixture was refluxed for 2 hours and then cooled to room temperature. Excess chloroform and thionyl chloride was removed by distillation. The residue oil  
15       was then fractionally distilled to give 45.3 g (78%) of the acid chloride (2), bp = 143-144°C.

      Acid chloride (2) was also be prepared by an alternative method which eliminated use of chloroform which has waste disposal and operator exposure  
20       difficulties. The alternate method also minimized the formation of 4-methylvaleric anhydride.

      To a solution of thionyl chloride (98.5 kg, 828 mol) and N,N-dimethylformamide (2 kg, 27 mol) was added 4-methylvaleric acid (74 kg, 637 mol) while  
25       maintaining a reaction temperature of 25-30°C. Hexanes (30 L) were added and the solution was maintained at 30-35°C for 1 hour and 15 minutes. The solution was then heated to 70-75°C for 1 hour and 10 minutes. The solution was subjected to atmospheric distillation  
30       until a solution temperature of 95°C was reached. After cooling, hexanes (30 L) were added and the solution was subjected to atmospheric distillation until a solution temperature of 97°C was reached. Distillation of the residual oil produced 79 kg (92%)  
35       of acid chloride (2), bp = -77°C, 60-65 mm Hg.

Step 2

To a solution of (4R,5S)-(+)-4-methyl-5-phenyl-2-oxazolidinone (5.27 g, 29.74 mmol) in 70 mL of anhydrous tetrahydrofuran at -78°C under argon atmosphere was added a 1.6 M solution of n-butyllithium (19 mL, 30.40 mmol) in hexanes slowly. The mixture was allowed to stir at -78°C for 15 minutes then the acid chloride (4.5 g, 33.43 mmol) was added to quench the reaction. The reaction was stirred at -78°C for 10 minutes then 0°C for 30 minutes. A saturated solution of sodium bicarbonate (50 mL) was added and the mixture was stirred at 0°C for 30 minutes. The organic layer was collected and the aqueous layer was extracted with ethyl acetate (3x). The organic extracts were combined and dried with anhydrous magnesium sulfate. It was then filtered and concentrated to give a colorless oil. The oil was then chromatographed with 8% ethyl acetate in hexanes on silica gel to give 7.56 g (82%) of the acyloxazolidinone (3) as a white solid.

Anal. Calcd for  $C_{16}H_{21}NO_3$ :

C, 69.79; H, 7.69; N, 5.09.

Found: C, 69.56; H, 7.63; N, 5.06.

Acyloxazolidinone (3) was also prepared by an alternate method which was conducted at -5°C to 0°C rather than -78°C which is difficult and expensive to achieve on a manufacturing scale. The alternate method also gave a crystalline solid from the reaction mixture rather than an oil which must be chromatographed.

To a solution of 4-methyl-5-phenyl-2-oxazolidinone (64 g, 0.36 mol) in anhydrous tetrahydrofuran (270 g) at -5°C was added a 15% solution of n-butyllithium in hexane (160 g, 0.37 mol) over a temperature range of -5°C to 0°C. Acid chloride (2) (48.6 g, 0.36 mol) was added at -10°C to 0°C. The reaction was quenched with a solution of water (90 mL) and sodium bicarbonate

(4 g). Ethyl acetate (200 g) was added and the layers were separated. The organic layer was extracted with water (2 x 50 mL) and the aqueous phases were back extracted with ethyl acetate (100 g). The organic  
5 extracts were combined and approximately 150 mL of solvent was removed by distillation. Atmospheric distillation was continued and heptane (2 x 200 g) was added until a vapor temperature of 95°C was reached. The solution was cooled to 5°C. The product was  
10 collected by filtration, washed with cold heptane, and dried to give 79 g (80%) of acyloxazolidinone (3).

### Step 3

To a solution of diisopropylamine (4.8 mL,  
15 34.25 mmol) in 30 mL of anhydrous tetrahydrofuran at 0°C under argon atmosphere was added a 1.6 M solution of n-butyllithium (21 mL, 33.60 mmol) in hexanes slowly. The solution was stirred at 0°C for 30 minutes then cooled to -78°C. A solution of the  
20 acyloxazolidinone (3) (7.56 g, 27.46 mmol) in 30 mL of anhydrous tetrahydrofuran was added and the pale yellow solution was stirred at -78°C for 30 minutes. Benzyl  $\alpha$ -bromoacetate was added and the resulting solution was stirred at -25°C for 2 hours. The reaction mixture was  
25 quenched with a half-saturated ammonium chloride solution and extracted by ethyl acetate (2x). The combined organic layers were dried with anhydrous magnesium sulfate and then filtered and concentrated to give a colorless oil. The oil was then chromatographed  
30 with 8% ethyl acetate in hexanes on silica gel to give 6.16 g (53%) of the acyloxazolidinone (4) as a white solid.

Anal. Calcd for  $C_{25}H_{29}NO_5$ :

C, 70.90; H, 6.90; N, 3.31.

35 Found: C, 70.47; H, 6.87; N, 3.45.



Acyloxazolidinone (4) was also prepared by an alternate method that was advantageous in that the reaction was conducted a higher temperature (-35°C to -25°C rather than -78°C) and an expensive and difficult chromatographic separation was avoided.

Acyloxazolidinone (3) (85 kg, 308 mol) was dissolved in anhydrous tetrahydrofuran (201 kg) and cooled to -30°C. Lithium diisopropyl amine (340 mol) in methyl-t-butyl ether/hexane was added while maintaining a reaction temperature of -35°C to -25°C. Benzyl bromoacetate (85 kg, 371 mol) was then added while maintaining a reaction temperature of -35°C to -25°C. Water (60 kg) and methyl-t-butyl ether (93 kg) were added and the mixture was allowed to warm to 18°C. The layers were separated and the organic layer was extracted with a solution of water (40 L) and sodium chloride (7 kg). The layers were separated and the organic layer was concentrated to 200 liters by distillation. Isopropyl alcohol (200 L) was added and the solution was again concentrated to 200 liters by distillation. Isopropyl alcohol (425 L) and water (160 L) were added and the mixture was heated to 50°C. The solution was cooled to 18°C. The product was collected by filtration, washed with isopropyl alcohol/water and dried under reduced pressure to give 58.7 kg (49% yield) of acyloxazolidinone (4) as a solid.

#### Step 4

To a pre-cooled (0°C) solution of the acyloxazolidinone (4) (24.3 g, 57.38 mmol) in 600 mL of tetrahydrofuran was added a solution of 30% hydrogen peroxide (23.7 mL) in 320 mL of 0.2 M lithium hydroxide solution via a dropping funnel in 20 minutes. The reaction mixture was allowed to stir at 0°C for 4 hours. A solution of sodium meta-bisulphite (62.2 g, 0.33 mol) in 320 mL of water was then added slowly to

quench the reaction. The mixture was stirred at 0°C for 20 minutes. Excess tetrahydrofuran was removed on a rotavap. The aqueous residue was extracted with ethyl acetate (3 x 350 mL). The combined organic  
5 extracts were dried with anhydrous magnesium sulfate and then filtered. The oily residue after concentration was chromatographed by 40% ethyl acetate in hexane on silica gel to give 13.34 g (88%) of the acid (5) as a clear oil. The column was then eluted  
10 with 50% ethyl acetate in hexane to give the oxazolidinone chiral auxiliary.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) of acid (5): δ 9.80 (br s, 1H), 7.36 (m, 5H), 5.14 (narrow ABq, 2H, J<sub>AB</sub>=11.4 Hz), 2.80 (m, 1H), 2.63 (ABX, 2H, J<sub>AB</sub>=16.75 Hz, J<sub>AB</sub>=9.13 Hz, J<sub>BX</sub>=5.16 Hz, U<sub>AB</sub>=73.20 Hz), 1.66 (m, 2H), 1.33 (m, 1H),  
15 0.93 (d, 3H, J=7.32 Hz), 0.91 (d, 3H, J=6.45 Hz).

In an alternate method, after concentration of the reaction to an oily residue, hexane or heptane may be added in order to precipitate the oxazolidinone chiral  
20 auxiliary. Filtration then yields the chiral auxiliary in 80% recovery. The hexane or heptane filtrate containing acid (5) is then extracted with either an ethanol water solution or with warm water to remove any remaining chiral auxiliary. This alternative method  
25 avoids a costly and difficult chromatographic separation of the chiral auxiliary from the acid (5).

#### Step 5

To a solution of the acid (5) (13.34 g, 50.47 mmol) in 460 mL anhydrous tetrahydrofuran at 0°C  
30 under argon was added borane dimethyl sulfide complex (10 M, 11.2 mL, 112.0 mmol) slowly. The reaction mixture was stirred at 0°C for 30 minutes then room temperature for 4 hours. The reaction was cooled to  
35 0°C and 250 mL of methanol was added slowly. The mixture was stirred at 0°C for 30 minutes and excess

solvent was removed under vacuum. The resulting oil was chromatographed by 15% ethyl acetate in hexanes on silica gel to give 10.59 g (84%) of the alcohol (6) as a colorless oil.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.37 (m, 5H), 5.14 (s, 2H), 3.57 (ABX, 2H, J<sub>AB</sub>=10.99 Hz, J<sub>AX</sub>=4.34 Hz, J<sub>BX</sub>=6.85 Hz, ν<sub>AB</sub>=51.71 Hz), 2.42 (ABX, 2H, J<sub>AB</sub>=15.26 Hz, J<sub>AX</sub>=7.60 Hz, J<sub>BX</sub>=5.56 Hz, ν<sub>AB</sub>=18.81 Hz), 2.15 (m, 1H), 1.87 (br s, 1H), 1.63 (m, 1H), 0.93 (m, 2H), 0.88 (d, 3H, J=6.15 Hz), 0.87 (d, 3H, J=6.45 Hz).

#### Step 6

To a solution of the alcohol (6) (10.22 g, 40.82 mmol) in 50 mL of anhydrous pyridine at 0°C was added tosyl chloride (8.60 g, 45.11 mmol). The reaction mixture was stirred at 0°C for 15 minutes then stood overnight in a refrigerator at 4°C. The reaction mixture was diluted with 160 mL of ethyl acetate and 100 mL of water. The mixture was cooled to 0°C in an ice-water bath and then concentrated hydrochloric acid was added slowly to neutralize excess pyridine (until pH 2). The organic layer was collected and the aqueous layer was extracted with ethyl acetate (3 x 100 mL).

The combined organics were dried with anhydrous magnesium sulfate and then filtered. The resulting pale yellow oil after concentration was chromatographed by 10% ethyl acetate in hexanes on silica gel to give 14.44 g (87%) of the tosylate (7) as a colorless oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.77 (d, 2H, J=8.27 Hz), 7.34 (m, 7H), 5.07 (s, 2H), 4.00 (ABX, 2H, J<sub>AB</sub>=9.77 Hz, J<sub>AX</sub>=4.07 Hz, J<sub>BX</sub>=5.69 Hz, ν<sub>AB</sub>=27.58 Hz), 2.44 (s, 1H), 2.44-2.20 (m, 3H), 1.46 (m, 1H), 1.28-1.02 (m, 2H), 0.81 (d, 6H, J=6.58 Hz).

The tosylate (7) was also prepared from acid (5) in an alternate method. This method was advantageous over the previous procedure above since it minimized

the amount of  $\beta$ -isobutyl- $\gamma$ -lactone produced as a by-product in the reaction above.

A solution of acid (5) (22.3 kg, 84.4 mol) in methyl-t-butyl ether (198 kg) was cooled to -6°C. Borane-methyl sulfide complex (15.6 kg, 177 mol) was added while maintaining a reaction temperature of 5°C or less. The mixture was then warmed to 20°C and stirred for two hours. The mixture was cooled to 0°C and methanol (24 L) was added while maintaining a reaction temperature of 5°C or less. Water (132 L) was added at a temperature of 15°C or less. The phases were separated and the aqueous phase was extracted with methyl-t-butyl ether (27 kg). The organic were combined and extracted with water (72 L). The solution was concentrated to an oil by distillation and ethyl acetate (23 kg) was added. The solution was again concentrated to an oil by distillation to give alcohol (6). Pyridine (53 kg) was added. The solution was cooled to 1°C and para-toluenesulfonyl chloride (23 kg, 121 mol) was added while maintaining a reaction temperature of -5°C to 5°C. The mixture was stirred at 2°C for 8 hours then warmed to 20°C. Water (12 L) was added while maintaining a reaction temperature of 23°C or less. The mixture was cooled to 1°C and aqueous hydrochloric acid (52 kg concentrated acid in 63 L water) was added. Methyl-t-butyl ether (296 kg) was added and the mixture was warmed to 18°C. The phases were separated and the aqueous phase was extracted with methyl-t-butyl ether (74 kg). The organic phases were combined and extracted with aqueous hydrochloric acid (0.6 kg concentrated hydrochloric acid in 20 liters water), aqueous sodium bicarbonate (2.7 kg sodium bicarbonate in 50 liters water), and water (30 L). The organic solution was concentrated to an oil by distillation. Methyl-t-butyl ether (19 kg) was added and the mixture was again concentrated to an oil. The

resulting product was dissolved in methyl-t-butyl ether (37.9 kg) and stored as a solution. Weight of tosylate (7) contained in methyl-t-butyl ether solution 30.1 kg (88% yield).

5

Step 7

10 A mixture of the tosylate (7) (14.44 g, 35.70 mmol) and sodium azide (5.50 g, 84.59 mmol) in 180 mL of anhydrous dimethylsulfoxide was heated at 65°C overnight. The reaction mixture was cooled to room temperature and 900 mL of water was added. The mixture was extracted (4x) with a total of 2 L of hexanes. The combined organic extracts were dried with anhydrous magnesium sulfate and then filtered. The filtrate was concentrated and the resulting oil was then chromatographed by 8% ethyl acetate in hexanes on silica gel to give 8.55 g (87%) of the azide (8) as a colorless oil.

15 <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.37 (m, 5H) 5.14 (s, 2H), 3.33 (ABX, 2H, J<sub>AB</sub>=12.27 Hz, J<sub>AX</sub>=4.95 Hz, J<sub>BX</sub>=6.10 Hz, ν<sub>AB</sub>=22.87 Hz), 2.39 (m, 2H), 2.19 (m, 1H), 1.62 (m, 1H), 1.20 (m, 2H), 0.88 (d, 6H, J=6.44 Hz).

20

Step 8

25 To a solution of the azide (8) (8.55 g, 31.05 mmol) in 500 mL of tetrahydrofuran was added 62 mL of a 1N aqueous hydrochloric acid solution and 1 g of 10% palladium on carbon catalyst. The mixture was shaken overnight at room temperature on a Parr apparatus. The catalyst was removed by filtration over a pad of celite. The filtrate was concentrated and 50 mL of a 1N aqueous hydrochloric acid solution was added. The aqueous solution was washed with ether (3 x 50 mL). The aqueous layer was collected and then chromatographed on a Dowex 50Wx8 (H<sup>+</sup> form) column eluted with a 0.5N ammonium hydroxide solution.

30

35

Fractions containing the amino acid (Ninhydrin positive) were collected and then lyophilized to give 3.2 g (65%) of the amino acid (9) as a white solid. mp = 175-176°C;  $[\alpha]_D^{23} = 10.520$  (1.06, H<sub>2</sub>O).

5

## EXAMPLE 2

### (S) - (+) - 4-amino-3-(2-methylpropyl)butanoic acid

10 This compound was prepared in the same manner as Example 1, except that amino acid (9) is prepared from azide (8) by a 2 step process utilizing an intermediate azide (8a) which is subsequently reduced (the 1 step reduction approach identified as step 8 is described above). The synthetic procedure of Example 2 is depicted in Chart Ia.

15

### Step 1: Preparation of Intermediate Azide (8a)

20 Azide (8) (10.7 g, 0.040 mol) in ethanol (100 mL) and water (20 mL) was treated with 50% aqueous sodium hydroxide (9.8 g). The mixture was stirred at 30°C for 45 minutes. Ethanol was removed under reduced pressure until 30 g of liquid remained, water (100 mL) was added and the mixture was extracted with methyl-t-butyl ether (4 x 100 mL). The methyl-t-butyl ether extracts were extracted with 1 M sodium hydroxide and the aqueous  
25 phases were combined and acidified to pH 1.6 with concentrated hydrochloric acid. The aqueous mixture was then extracted with methyl-t-butyl ether (2 x 100 mL) and the organic extracts were combined and concentrated under reduced pressure. The resulting oil  
30 was dissolved in heptane (50 mL) and extracted with saturated aqueous sodium bicarbonate (2 x 40 mL). The aqueous extracts were extracted with heptane (50 mL), combined and acidified to pH 1.6 with concentrated hydrochloric acid. The aqueous mixture was extracted  
35 with heptane (2 x 50 mL). The heptane extracts were extracted with water (40 mL), combined, and

concentrated under reduced pressure to give 5.4 g (75%) of intermediate azide (8a) as an oil.

$^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ):  $\delta$  10.8 (br s, 1H), 3.36 (m, 2H), 2.38 (m, 2H), 2.18 (m, 1H), 1.64 (m, 1H), 1.25 (m, 2H), 0.91 (d, 6H,  $J=6.56$  Hz).

Step 2: Synthesis of Amino Acid (9) from Intermediate Azide (8a)

Intermediate azide (8a) (12.7 g, 68.6 mol) was dissolved in methyl-t-butyl ether (80 kg). The mixture was subjected to catalytic hydrogenation in the presence of 5% palladium on carbon (2.0 kg of 50% water wet) at 49 to 55 psi of hydrogen until intermediate azide (8a) has been consumed. The mixture was filtered and the solid was washed with methyl-t-butyl ether (30 kg). The solid was dissolved in a solution of hot isopropanol (75 kg) and water (60 kg) and the solution was filtered. The isopropanol water solution was cooled to  $-3^\circ\text{C}$  and the product was filtered and washed with cold isopropanol (16 kg). The solid was dried under reduced pressure to give 6.4 kg (59%) of amino acid (9).

This reduction may be conducted in a variety of solvents. Successful reductions have been carried out in heptane, ethanol/water, isopropanol, isopropanol/water, methanol/water, and tetrahydrofuran/water as well as methyl-t-butyl ether.

EXAMPLE 3

(S)-(+)-4-amino-3-(2-methylpropyl)butanoic acid

The following "steps", refer to Chart II. All reactions were carried out under an atmosphere of nitrogen.

Step 1

To a solution of 4-methylvaleric acid (50.0 g, 0.43 mol) in 100 mL of anhydrous chloroform was added thionyl chloride (60 mL, 0.82 mol). The reaction mixture was refluxed for 2 hours and then cooled to room temperature. Excess chloroform and thionyl chloride was removed by distillation. The residue oil was then fractionally distilled to give 45.3 g (78%) of the acid chloride (102), bp = 143-144°C.

Acid chloride (102) was also prepared by an alternative method which eliminated use of chloroform which has waste disposal and operator exposure difficulties. The alternate method also minimized the formation of 4-methylvaleric anhydride.

To a solution of thionyl chloride (98.5 kg, 828 mol) and N,N-dimethylformamide (2 kg, 27 mol) was added 4-methylvaleric acid (74 kg, 637 mol) while maintaining a reaction temperature of 25-30°C. Hexanes (30 L) were added and the solution was maintained at 30°C to 35°C for 1 hour and 15 minutes. The solution was then heated to 70°C to 75°C for 1 hour and 10 minutes. The solution was subjected to atmospheric distillation until a solution temperature of 95°C was reached. After cooling, hexanes (30 L) were added and the solution was subjected to atmospheric distillation until a solution temperature of 97°C was reached. Distillation of the residual oil produced 79 kg (92%) of acid chloride (102), bp = -77°C, 60-65 mm Hg.

Step 2

To a solution of (4R,5S) - (+) - 4-methyl-5-phenyl-2-oxazolidinone (5.27 g, 29.74 mmol) in 70 mL of anhydrous tetrahydrofuran at -78°C under argon atmosphere was added a 1.6 M solution of n-butyllithium (19 mL, 30.40 mmol) in hexanes slowly. The mixture was allowed to stir at -78°C for 15 minutes then the acid



chloride (4.5 g, 33.43 mmol) was added to quench the reaction. The reaction was stirred at -78°C for 10 minutes then 0°C for 30 minutes. A saturated solution of sodium bicarbonate (50 mL) was added and the mixture was stirred at 0°C for 30 minutes. The organic layer was collected and the aqueous layer was extracted with ethyl acetate (3x). The organic extracts were combined and dried with anhydrous magnesium sulfate. It was then filtered and concentrated to give a colorless oil. The oil was then chromatographed with 8% ethyl acetate in hexanes on silica gel to give 7.56 g (82%) of the acyloxazolidinone (103) as a white solid.

Anal. Calcd for  $C_{16}H_{21}NO_3$ :

C, 69.79; H, 7.69; N, 5.09.

Found: C, 69.56; H, 7.63; N, 5.06.

Acyloxazolidinone (103) was also prepared by an alternate method which was conducted at -5°C to 0°C rather than -78°C which is difficult and expensive to achieve on a manufacturing scale. The alternate method also gave a crystalline solid from the reaction mixture rather than an oil which must be chromatographed.

To a solution of 4-methyl-5-phenyl-2-oxazolidinone (64 g, 0.36 mol) in anhydrous tetrahydrofuran (270 g) at -5°C was added a 15% solution of n-butyllithium in hexane (160 g, 0.37 mol) over a temperature range of -5°C to 0°C. Acid chloride (102) (48.6 g, 0.36 mol) was added at -10°C to 0°C. The reaction was quenched with a solution of water (90 mL) and sodium bicarbonate (4 g). Ethyl acetate (200 g) was added and the layers were separated. The organic layer was extracted with water (2 x 50 mL) and the aqueous phases were back extracted with ethyl acetate (100 g). The organic extracts were combined and approximately 150 mL of solvent was removed by distillation. Atmospheric distillation was continued and heptane (2 x 200 g) was

added until a vapor temperature of 95°C was reached. The solution was cooled to 5°C. The product was collected by filtration, washed with cold heptane, and dried to give 79 g (80%) of acyloxazolidinone (103).

Step 3

To a solution of diisopropylamine (7.6 g, 0.075 mol) in anhydrous tetrahydrofuran (10 mL) at 0°C under nitrogen was added a 1.6 M *n*-butyllithium in hexane (47 mL, 0.075 mol) while maintaining a temperature of -5°C to 0°C. The resulting solution was added to a solution of acyloxazolidinone (103) (18.6 g, 0.068 mol) in tetrahydrofuran (160 mL) at -55°C to -45°C. The solution was stirred at -55°C to -45°C for 30 minutes. The solution was then added to a solution of *t*-butyl bromoacetate (14.6 g, 0.075 mol) in tetrahydrofuran at -55°C to -45°C. The solution was cooled to -65°C and allowed to warm to 10°C over a period of 2 hours. The reaction mixture was quenched with the addition of saturated aqueous ammonium chloride and extracted with ethyl acetate. The organic layer was dried (MgSO<sub>4</sub>), filtered, and the solvent was removed under reduced pressure. The residue was recrystallized from heptanes, filtered, and dried under reduced pressure to give 18 g (68%) of acyloxazolidinone (104).

<sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>): δ 7.4-7.2 (m, 5H), 5.65 (d, 1H, J=7.09 Hz), 4.74 (m, 1H), 4.26 (m, 1H), 2.69 (m, 1H), 2.44 (m, 1H), 1.65-1.45 (m, 2H), 1.39 (s, 9H), 0.93 (m, 6H), 0.89 (d, 3H, J=7.87 Hz).

Alternatively, the order of addition of the reagents may be reversed. *t*-Butyl bromoacetate may be added to the solution containing diisopropylamine, *n*-butyllithium and acyloxazolidinone (103). The final product isolation may also be conducted by doing a distillation and replacing the solvents present (hexane

and tetrahydrofuran) with isopropyl alcohol. Acyloxazolidinone (104) then crystallizes from the isopropyl alcohol solution. The following experimental procedure illustrates this alternative.

5           To a solution of diisopropylamine (23.1 g, 0.229 mol) in anhydrous tetrahydrofuran (30 mL) at 0°C under nitrogen was added a 2.5 M n-butyllithium in hexane (92 mL, 0.229 mol) while maintaining a temperature of -5°C to 0°C. The resulting solution was added to a solution of acyloxazolidinone (103) (60.0 g, 0.218 mol) in tetrahydrofuran (400 mL) at -45°C to 40°C. The solution was stirred at -45°C to -40°C for 30 minutes. t-Butyl bromoacetate (44.6 g, 0.229 mol) was then added to the reaction solution at -45°C to -40°C. The solution was allowed to warm to 10°C over a period of 2 to 3 hours. The reaction mixture was quenched with the addition of saturated aqueous ammonium chloride. The organic layer was separated from the water layer. The solvent was removed under reduced pressure and replaced with isopropyl alcohol. The product crystallized from isopropyl alcohol and was filtered and dried under reduced pressure to give 53.8 g (63%) of acyloxazolidinone (104).

#### 25    Step 4

          To a precooled (5°C) solution of acyloxazolidinone (104) (60.0 g, 0.15 mol) in tetrahydrofuran (266 g) was added a solution of 30% hydrogen peroxide (71 g), 9.4 g lithium hydroxide monohydrate (0.22 mol) and water (120 mL) over a period of 35 minutes so as to maintain a reaction temperature of 5°C. The mixture was stirred at 3-5°C for 2.5 hours. The reaction was quenched by addition of a solution of sodium sulfite (50 g), sodium bisulfite (27 g), and water (310 mL) at a temperature of less than 29°C. Heptane (100 mL) and methyl-t-butyl ether (100 mL) were added and the layers were

separated. The aqueous layer was extracted with methyl-t-butyl ether (100 mL) and the organic layers were combined. The solvent was replaced with heptane by distillation and the resulting heptane solution (400 mL) was cooled to 5°C. The resulting solids were filtered and the filtrate was extracted with warm water (2 x 150 mL, 1 x 200 mL, 1 x 300 mL). The solution was concentrated by evaporation to give 34.5 g (97%) acid (105) as an oil.

$^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ):  $\delta$  11.5 (br, s, 1H), 2.85 (m, 1H), 2.67-2.29 (m, 2H), 1.60 (m, 1H), 1.44 (s, 9H), 1.32 (m, 2H), 0.92 (m, 6H).

#### Step 5

Acid (105) (72.4 g, 0.314 mol) was dissolved in tetrahydrofuran (360 mL) and cooled to 0°C. A 2.0 M solution of borane dimethylsulfide complex in tetrahydrofuran (178 mL, 0.356 mol) was added at 0°C. The solution was allowed to warm to 48°C then cooled to 25°C. After 2 hours and 45 minutes, the reaction was quenched with the addition of methanol (300 mL) and the solvent was removed under reduced pressure. Additional methanol (300 mL) was added and the solution was concentrated under reduced pressure to give 66 g (97%) of alcohol (106) as an oil.

$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta$  3.62 (m, 1H), 3.45 (m, 1H), 2.44 (br s, 1H), 2.36-2.21 (m, 2H), 2.05 (m, 1H), 1.64 (m, 1H), 1.45 (s, 9H), 1.24-1.04 (m, 2H), 0.91 (m, 6H).

#### Step 6

Alcohol (107) (51.9 g, 0.24 mol) was dissolved in pyridine (130 mL) and cooled to 5°C. p-Toluene sulfonyl chloride (57.2 g, 0.30 mol) was added and the mixture was stirred at 22°C for 21 hours. The reaction was quenched with the addition of water (95 mL) and 18% aqueous hydrochloric acid (300 mL) at less than 300°C.

Methyl-t-butyl ether (350 mL) was added and the layers were separated. The aqueous layer was extracted with methyl-t-butyl ether (350 mL). The organic layers were combined, washed with 1% aqueous hydrochloric acid (2 x 100 mL), saturated aqueous sodium bicarbonate (1 x 150 mL), and water (1 x 100 mL). The organic solution was treated with decolorizing charcoal, filtered, and evaporated to give 77 g (86%) of the tosylate (107) as an oil.

$^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.78 (d, 2H,  $J=8.25$  Hz), 7.34 (d, 2H,  $J=8.25$  Hz), 3.96 (m, 2H), 2.45 (s, 3H), 2.32-2.12 (m, 3H), 1.6-1.4 (m, 1H), 1.40 (s, 9H), 1.2-1.1 (m, 2H), 0.83 (m, 6H).

#### Step 7

Tosylate (107) (65 g, 0.175 mol) was dissolved in dimethyl sulfoxide (40 mL). The dimethyl sulfoxide solution along with additional dimethyl sulfoxide (10 mL) was then added to a solution of sodium azide (11 g, 0.26 mol) in dimethyl sulfoxide (450 g) at 63°C. The mixture was then stirred at 65°C for 6 hours. Water (140 mL) and heptane (250 mL) were added to the reaction and the layers were separated. The aqueous layer was extracted with heptane (250 mL) and the organic layers were combined. The solvent was removed under reduced pressure to give 42 g (95%) of the azide (108) as an oil.

$^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ ):  $\delta$  3.32 (m, 2H), 2.22 (m, 2H), 2.15 (m, 1H), 1.63 (m, 1H), 1.46 (s, 9H), 1.19 (m, 2H), 0.89 (m, 6H).

#### Step 8

Azide (108) (36.3 g, 0.15 mol) was placed in 88% aqueous formic acid (365 mL). The mixture was stirred at 30°C for 4.5 hours. Decolorizing charcoal was added and the mixture was filtered and concentrated under

reduced pressure to give an oil. Heptane (250 mL) was added and the mixture was vacuum distilled to give an oil. Water (125 mL) and heptane (250 mL) were added and mixed vigorously. The layers were separated and the water layer was washed with heptane (250 mL). The heptane layers were combined and concentrated under reduced pressure to give 24.6 g (88%) of intermediate azide (108a) as an oil.

Alternatively, aqueous hydrochloric acid may be used rather than aqueous formic acid in order to conduct the hydrolysis.

#### Step 9

Intermediate azide (108a) (12.7 g, 68.6 mol) was dissolved in methyl-t-butyl ether (80 kg). The mixture was subjected to catalytic hydrogenation in the presence of 5% palladium on carbon (2.0 kg of 50% water wet) at 49-55 psi of hydrogen until intermediate azide (108a) has been consumed. The mixture was filtered and the solid was washed with methyl-t-butyl ether (30 kg). The solid was dissolved in a solution of hot isopropanol (75 kg) and water (60 kg) and the solution was filtered. The isopropanol water solution was cooled to -3°C and the product was filtered and washed with cold isopropanol (16 kg). The solid was dried under reduced pressure to give 6.4 kg (59%) of amino acid (109).

This reduction may be conducted in a variety of solvents. Successful reductions have been carried out in heptane, ethanol/water, isopropanol, isopropanol/water, methanol/water, and tetrahydrofuran/water as well as methyl-t-butyl ether.

The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be

5

Obviously many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims wherein reference numerals are merely for convenience and are not to be in any way limiting, the invention may be practiced otherwise than as specifically described.

CHART I






CHART Ia






CHART II



CLAIMS

What is Claimed is:

1. A compound selected from the following formula




I

wherein  $\text{R}_1$  is a straight or branched alkyl of from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms;  $\text{R}_2$  is hydrogen or methyl; and  $\text{R}_3$  is hydrogen, methyl, or carboxyl; individual enantiomers thereof; and pharmaceutically acceptable salts thereof; with the proviso that when each of  $\text{R}_2$  and  $\text{R}_3$  is hydrogen,  $\text{R}_1$  is other than methyl.

2. A compound of Claim 1 wherein  $\text{R}_1$  is a straight or branched alkyl having from 1 to 6 carbon atoms.
3. A compound of Claim 2 wherein the alkyl group has 4 carbon atoms.
4. A compound of Claim 3 which is 4-amino-3-(2-methylpropyl)butanoic acid.
5. A compound of Claim 3 which is S-(+)-4-amino-3-(2-methylpropyl)butanoic acid.
6. A compound of Claim 3 which is R(-)-4-amino-3-(2-methylpropyl)butanoic acid.
7. A method of treating a patient having seizure disorders which comprises administering to said

patient an effective amount of a compound of the formula




wherein  $\text{R}_{11}$  is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl group having from 3 to 6 carbon atoms;  $\text{R}_{12}$  is hydrogen or methyl; and  $\text{R}_{13}$  is hydrogen, methyl, or carboxyl; individual enantiomers thereof; and pharmaceutically acceptable salts thereof.


8. The method of Claim 7 wherein  $\text{R}_{11}$  is a straight or branched alkyl group having from 1 to 6 carbon atoms.
9. The method of Claim 8 wherein the alkyl group has 4 carbon atoms.
10. The method of Claim 9 wherein the compound is 4-amino-3-(2-methylpropyl)butanoic acid.
11. The method of Claim 9 wherein the compound is S-(+)-4-amino-3-(2-methylpropyl)butanoic acid.
12. The method of Claim 9 wherein the compound is R-(-)-4-amino-3-(2-methylpropyl)butanoic acid.
13. The method of Claim 7 wherein the seizure disorder is the result of epilepsy, acerebral ischemic condition, Parkinson's disease, Huntington's disease, or a spastic condition.

14. The method of Claim 13 wherein the seizure disorder is the result of epilepsy.
15. The method of Claim 13 wherein the seizure disorder is the result of a spastic condition.
16. A pharmaceutical composition comprising a compound of Claim 1 together with a pharmaceutically acceptable carrier.
17. The composition of Claim 16 wherein the compound is one wherein  $R_1$  is a straight or branched alkyl group having from 1 to 6 carbon atoms.
18. The composition of Claim 17 wherein the compound is 4-amino-3-(2-methylpropyl)butanoic acid.
19. The composition of Claim 17 wherein the compound is S-(+)-4-amino-3-(2-methylpropyl)butanoic acid.
20. The composition of Claim 17 wherein the compound is R-(-)-4-amino-3-(2-methylpropyl)butanoic acid.
21. A process for preparing a chiral compound of Formula I which comprises converting an acid of the formula  $\text{HOC}(=\text{O})\text{CH}(\text{R}_1)(\text{R}_2)$  to the corresponding acid chloride of the formula  $\text{ClC}(=\text{O})\text{CH}(\text{R}_1)(\text{R}_2)$  which was added to a solution of (4R,5S)-(+)-4-methyl-5-phenyl-2-oxazolidinone and n-butyllithium at  $-78^\circ\text{C}$  under argon to give an oxazolidinone derivative of the formula


14. The method of Claim 13 wherein the seizure disorder is the result of epilepsy.
15. The method of Claim 13 wherein the seizure disorder is the result of a spastic condition.
16. A pharmaceutical composition comprising a compound of Claim 1 together with a pharmaceutically acceptable carrier.
17. The composition of Claim 16 wherein the compound is one wherein  $R_1$  is a straight or branched alkyl group having from 1 to 6 carbon atoms.
18. The composition of Claim 17 wherein the compound is 4-amino-3-(2-methylpropyl)butanoic acid.
19. The composition of Claim 17 wherein the compound is S-(+)-4-amino-3-(2-methylpropyl)butanoic acid.
20. The composition of Claim 17 wherein the compound is R-(-)-4-amino-3-(2-methylpropyl)butanoic acid.
21. A process for preparing a chiral compound of Formula I which comprises converting an acid of the formula  $\text{HOC}(=\text{O})\text{CH}(\text{R}_1)(\text{R}_2)$  to the corresponding acid chloride of the formula  $\text{ClC}(=\text{O})\text{CH}(\text{R}_1)(\text{R}_2)$  which was added to a solution of (4R,5S)-(+)-4-methyl-5-phenyl-2-oxazolidinone and n-butyllithium at  $-78^\circ\text{C}$  under argon to give an oxazolidinone derivative of the formula




which was treated with benzyl  $\alpha$ -bromoacetate to give the ester



which was treated with hydrogen peroxide and lithium oxide followed by treatment with sodium metabisulfite to give compounds of the formula




which is treated with borane dimethyl sulfide complex to give the alcohol



which is converted to the corresponding tosylate (Formula A wherein P is Tso) which is further

converted to the azide (Formula A wherein P is N<sub>3</sub>) and the azide is reduced to the amine of the formula



wherein R<sub>1</sub> and R<sub>2</sub> have the meanings defined in Claim 1, Ph is phenyl, Me is methyl, and Bn is benzyl.

22. A compound which is
  - 4-methyl-5-phenyl-2-oxazolidinone,
  - 4-methyl-(2-methylpropyl)-2-dioxo-5-phenyl-3-oxazolidine butanoic acid, phenylmethyl ester,
  - 4-methyl-pentanoyl chloride,
  - 4-methyl-3-(4-methyl-1-oxopentyl)-5-phenyl-2-oxazolidinone,
  - 2-(2-methylpropyl)-butanedioic acid,
  - 4-(phenylmethyl)ester,
  - 3-(azidomethyl)-5-methyl-hexanoic acid, phenylmethyl ester,
  - 3-(hydroxymethyl)-5-methyl-hexanoic acid, phenylmethyl ester,
  - 5-methyl-3-[[[(4-methylphenyl)sulfonyl]oxy]-methyl]-hexanoic acid, phenylmethyl ester,
  - 3-(azidomethyl)-5-methyl-hexanoic acid,
  - 2-(2-methylpropyl)-1,4-butanedioic acid,
  - 4-(1,1-dimethylethyl) ester,
  - 3-(azidomethyl)-5-methyl-, 1,1-dimethylethyl ester,
  - 3-(hydroxymethyl)-5-methyl-hexanoic acid, 1,1-dimethyl ester,




5-methyl-3-[[[(4-methyl(phenyl)sulfonyl]oxy]-  
methyl-hexanoic acid, 1,1-dimethylethyl ester, or  
4-methyl-(2-methylpropyl)-2-dioxo-5-phenyl-  
3-oxazolidinebutanoic acid, 1,1-dimethylethyl  
ester.

23. A compound which is  
(S)-3-(azidomethyl)-5-methyl-hexanoic acid.

24. A compound which is  
(S)-3-(azidomethyl)-5-methyl-hexanoic acid,  
1,1-dimethylethyl ester.

25. A compound which is  
(S)-5-methyl-3-[[[(4-methyl(phenyl)sulfonyl]-  
oxy]methyl-hexanoic acid, 1,1-dimethylethyl ester,  
(S)-3-(hydroxymethyl)-5-methyl-,  
1,1-di-methylethyl ester,  
(S)-2-(2-methylpropyl)-1,4-butanedioic acid,  
4-(1,1-dimethylethyl) ester, or  
(S)-4-methyl-(2-methylpropyl)-2-dioxo-  
5-phenyl-3-oxazolidinebutanoic acid, 1,1-dimethyl-  
ethyl ester.


26. A process for preparing a chiral compound of the  
formula



I

wherein  $\text{R}_1$  is a straight or branched alkyl of from  
1 to 6 carbon atoms, phenyl, or cycloalkyl having  
from 3 to 6 carbon atoms;  $\text{R}_2$  is hydrogen or  
methyl; and  $\text{R}_3$  is hydrogen, methyl, or carboxyl,


which comprises hydrolyzing an azide of the formula



to an intermediate azide of the formula




and the intermediate azide is reduced to the amine of the formula




wherein  $\text{R}_1$  and  $\text{R}_2$  have the meanings defined in Claim 1, Ph is phenyl, Me is methyl, and Bn is benzyl.

27. A process as defined in Claim 26 wherein the azide is hydrolysed by treatment with sodium hydroxide.
28. A process as defined in Claim 26 further comprising the step of extraction of intermediate azide into an aqueous base.


29. A process as defined in Claim 28 further comprising the step of acidifying the aqueous extract.
30. A process as defined in Claim 26 wherein the intermediate azide is reduced under near neutral conditions to give the amino acid.
31. The amino acid obtained by the process defined in Claim 26.
32. A process for preparing a chiral compound of the formula




wherein  $R_1$  is a straight or branched alkyl of from 1 to 6 carbon atoms;  $R_2$  is hydrogen or methyl; and  $R_3$  is hydrogen, methyl, or carboxyl, which comprises hydrolyzing an azide of the formula



to an intermediate azide of the formula



and the intermediate azide is reduced to the amine  
of the formula




35 wherein  $\text{R}_1$  and  $\text{R}_2$  have the meanings defined in  
Claim 1, Ph is phenyl, and Me is methyl.

33. A process as defined in Claim 32 wherein the azide  
is hydrolysed by treatment with sodium hydroxide.
34. A process as defined in Claim 32 further  
comprising the step of extraction of intermediate  
azide into an aqueous base.
35. A process as defined in Claim 34 further  
comprising the step of acidifying the aqueous  
extract.
36. A process as defined in Claim 32 wherein the  
intermediate azide is reduced under near neutral  
conditions to give the amino acid.
37. The amino acid obtained by the process defined in  
Claim 32.

ABSTRACT

A compound of the formula



I

wherein R<sub>1</sub> is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R<sub>2</sub> is hydrogen or methyl; and R<sub>3</sub> is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.

Attorney's Docket No. P-320(NU)**COMBINED DECLARATION AND POWER OF ATTORNEY**(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL,  
DIVISIONAL, CONTINUATION OR CIP)

As a below named inventor, I hereby declare that:

**TYPE OF DECLARATION**

This declaration is of the following type: (check one applicable item below)

- ☐ original  
☐ design  
☐ supplemental

**NOTE:** If the declaration is for an international Application being filed as a divisional, continuation or continuation-in-part application do not check next item; check appropriate one of last three items.

☐ national stage of PCT

**NOTE:** If one of the follow 3 items apply then complete and also attach ADDED PAGES FOR DIVISIONAL, CONTINUATION OR CIP.

- ☐ divisional  
☐ continuation  
☒ continuation-in-part (CIP)

**INVENTORSHIP IDENTIFICATION**

**WARNING:** If the inventors are each not the inventors of all the claims an explanation of the facts, including the ownership of all the claims at the time the last claimed invention was made, should be submitted.

My residence, post office address and citizenship are as stated below next to my name, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**TITLE OF INVENTION**GABA AND L-GLUTAMIC ACID ANALOGS FOR ANTISEIZURE TREATMENT**SPECIFICATION IDENTIFICATION**

the specification of which: (complete (a), (b) or (c))

- (a) ☐ is attached hereto.  
 (b) ☒ was filed on May 18, 1993 as ☒ Serial No. 08/064,285 or Express Mail No., as Serial No. not yet known \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).

**NOTE:** Amendments filed after the original papers are deposited with the PTO which contain new matter are not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 CFR 1.67.

664223 6661660

(c) \_\_\_\_\_ was described and claimed in PCT International Application No. \_\_\_\_\_ filed on \_\_\_\_\_ and as amended under PCT Article 19 on \_\_\_\_\_ (if any).

#### ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 35, Code of Federal Regulations. § 1.56(a).

\_\_\_\_\_ In compliance with this duty there is attached an information disclosure statement 37 CFR 1.97.

#### PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

(complete (d) or (e))

(d) ☒ no such applications have been filed.

(e) \_\_\_\_\_ such applications have been filed as follows

**NOTE:** Where item (c) is entered above and the International Application which designated the U.S. claimed priority check item (e), enter the details below and make the priority claim.

#### EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIM UNDER 35 USC 119
			___ YES ___ NO
			___ YES ___ NO
			___ YES ___ NO
			___ YES ___ NO
			___ YES ___ NO

#### ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

---

---

---

POWER OF ATTORNEY

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (List name and registration number)

L.A. Ebling	34,153	H.W. Milton, Jr.	22,180
P.J. Ethington	17,299	J.P. Moran	20,941
J.C. Evans	20,124	O.E. Perry	19,969
R.L. Farris	25,112	S.L. Permut	28,388
F.J. Fodale	20,824	J.E. Shackelford	36,003
R.W. Hoffmann	33,711	D.J. Simonelli	36,680
K.I. Kohn	30,955	R.L. Stearns	36,937
J.F. Learman	17,069	J.D. Stevens	35,691
J.K. McCulloch	17,452	C.R. White	20,494
G.E. McGlynn III	33,737	See attached sheet for additional attorneys	

SEND CORRESPONDENCE TO

DIRECT TELEPHONE CALLS TO:

(NAME AND TELEPHONE NUMBER)

Kenneth I. Kohn  
Reising, Ethington, Barnard,  
Perry & Milton  
P.O. Box 4390  
Troy, MI 48099-9998

Kenneth I. Kohn  
(313) 689-3554

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

Full name of sole or first inventor Richard B. Silverman

Inventor's signature Richard B. Silverman

Date 7/6/93 Country of Citizenship U.S.A.

Residence Morton Grove, Illinois 60053

Post Office Address 7817 Beckwith Road

Morton Grove, Illinois 60053

Full name of second joint inventor, if any Ryszard Andruszkiewicz

Inventor's signature Ryszard Andruszkiewicz

Date 7/12/93 Country of Citizenship Poland

Residence Sopot, Poland

Post Office Address Kolberga 14C M27

81-881 Sopot, Poland



CHECK PRO. 3 BOX(ES) FOR ANY OF THE FOLLOWING ADDED  
PAGE(S) WHICH FORM A PART OF THIS DECLARATION

1 Signature for third and subsequent joint inventors. Number of  
pages added 1

\_\_\_\_ Signature by administrator(trix), executor(trix) or legal  
representative for deceased or incapacitated inventor. Number  
of pages added \_\_\_\_\_

\_\_\_\_ Signature for inventor who refuses to sign or cannot be reached  
by person authorized under 37 CFR 1.47. Number of pages  
added \_\_\_\_\_

\* \* \*

1 Added pages to combined declaration and power of attorney for  
divisional, continuation, or continuation-in-part (CIP)  
application. \_\_\_\_\_ Number of pages added 1

\* \* \*

\_\_\_\_ Authorization of attorney(s) to accept and follow instructions  
from representative.

\* \* \*

If no further pages form a part of this Declaration then end  
this Declaration with this page and check the following item

\_\_\_\_ This declaration ends with this page.

\*\*\*\*

1 Added page for additional attorneys of record.

Number of pages added 1

ADDED PAGE TO COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR SIGNATURE BY THIRD AND SUBSEQUENT INVENTORS

Full name of third joint inventor, if any Po-Wai Yuen

Inventor's signature 

Date 8/6/93 Country of Citizenship Hong Kong

Residence Ann Arbor, Michigan 48108

Post Office Address 2178 Maple Creek Circle

Ann Arbor, Michigan 48108

Full name of fourth joint inventor, if any Denis Martin Sobieray

Inventor's signature 

Date 8/7/93 Country of Citizenship U.S.A.

Residence Holland, Michigan 49424

Post Office Address 2178 South Bristol

Holland, Michigan 49424

Full name of fifth joint inventor, if any Lloyd Charles Franklin

Inventor's signature 

Date 8/9/93 Country of Citizenship U.S.A.

Residence Hamilton, Michigan 49419

Post Office Address 4391 137th Avenue

Hamilton, Michigan 49419

Full name of sixth joint inventor, if any Mark Alan Schwindt

Inventor's signature 

Date 8/9/93 Country of Citizenship U.S.A.

Residence Holland, Michigan 49424

Post Office Address 10443 Hunters Creek

Holland, Michigan 49424

# **ADDED PAGE TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR CIP APPLICATION**

*(complete this part only if this is a divisional, continuation or CIP application)*

## **CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S) UNDER 35 U.S.C. 120**

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information that is material to the examination of this application, namely, information where there is substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent, which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 USC 120:					
U.S. APPLICATIONS			Status (Check one )		
U.S. APPLICATIONS	U.S. FILING DATE	Patented	Pending	Abandoned	
1. 07/ 886,080	May 20, 1992		X		
2. 07/ 618,692	Nov. 27, 1990			X	
3. 0 /					
PCT APPLICATIONS DESIGNATING THE U.S.					
PCT APPLI- CATION NO.	PCT FILING DATE	U.S. SERIAL NOS. ASSIGNED (if any)			
4. _____					
5. _____					
6. _____					

(Added Page to Combined Declaration and Power of Attorney for Divisional, Continuation or CIP Application [1-2.1]—page 1

POWER OF ATTORNEY CONTINUED

Charles W. Almer, III	Reg. No. 36,731
Elizabeth M. Anderson	Reg. No. 31,585
Michael J. Atkins	Reg. No. 35,431
Jean B. Barish	Reg. No. 34,118
Ronald A. Daignault	Reg. No. 25,968
M. Andrea Ryan	Reg. No. 28,649
Francis J. Tinney	Reg. No. 33,069

(Added Page for Additional Attorneys of Record)